
Broaden your watchlist beyond GRAIL by scanning a curated 35 healthcare AI stocks that could also benefit as regulators warm to data driven cancer and diagnostics platforms.
To own GRAIL, you need to believe Galleri can evolve from a promising test into a large, economically sustainable screening business. That means enough volume, pricing power and reimbursement to eventually absorb high operating costs, Illumina royalties and current losses. The analyst consensus narrative on Simply Wall St leans on revenue growth expectations rather than near term profitability to support that view.
The recent FDA advisory committee support helps the regulatory narrative but does not resolve the biggest near term swing factor, which is still the eventual PMA decision and any follow on coverage terms. The key risk remains prolonged heavy cash burn if promotional pricing, overhead and royalty expense keep earnings and cash flow under strain.
The advisory committee vote in favor of Galleri’s safety, effectiveness and benefit risk profile is the announcement that matters most here. It directly feeds into the PMA review and the idea that Galleri could become the first multi cancer screening tool approved through that pathway, a key operational milestone for GRAIL.
That recommendation also connects to the catalysts in the analyst consensus narrative on Simply Wall St, which highlights potential Medicare coverage via the MCED Act and broader payer adoption. Execution risk still sits in the details, including future trial publications, coverage decisions and GRAIL’s ability to scale volumes while moving cost of goods toward the targeted US$230 per test level.
GRAIL's narrative projects US$378.7 million revenue and US$75.1 million earnings by 2029. This rests on analysts assuming 31.5% yearly revenue growth and an earnings swing of about US$481.3 million from a current loss of US$406.2 million to the 2029 forecast level.
Uncover why GRAIL's fair value indicates a 33% potential upside to its current price, which could narrow quickly as Galleri adoption and sentiment shift.
For GRAIL, the sharpest bearish twist is pricing. The lowest analysts were assuming only 20.9% yearly revenue growth and about US$294.4 million of sales by 2029, well below the consensus US$378.7 million. You can read that as a warning that even after this FDA panel news, those pre news views might shift in very different ways.
Explore 3 other GRAIL fair value estimates, including one that suggests as much as 78% downside from the current price!
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
Once you have formed a view on GRAIL, it can help to compare that thesis with other opportunities that share similar qualities or offer a very different risk profile. The Simply Wall St Screener lets you quickly filter for traits that match how you like to invest, whether that is resilience, income, or underappreciated growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com